Designs and analyses of psychotropic and behavioral interventions for the treatment of problem behavior among people with intellectual and developmental disabilities

American Journal on Intellectual and Developmental Disabilities

Volumn 116, Issue 4, 2011, Pages 315-328

  Courtemanche, Andrea B ^a   Schroeder, Stephen R ^a   Sheldon, Jan B ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

BEHAVIOR THERAPY; CHILD; DEVELOPMENTAL DISORDER; HUMAN; MENTAL DEFICIENCY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

BEHAVIOR THERAPY; CHILD; COMBINED MODALITY THERAPY; DEVELOPMENTAL DISABILITIES; HUMANS; MENTAL RETARDATION; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80053151703     PISSN: 19447558     EISSN: None     Source Type: Journal    
DOI: 10.1352/1944-7558-116.4.315     Document Type: Article

References (68)

1. Aman, M., Van Bourgondien, M., Wolford, P., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 1672-1681.
2. Aman, M., & Wolford, P. (1995). Consumer satisfaction with involvement in drug research: A social validity survey. Journal of the American Academy of Child & Adolescent Psychiatry, 34, 940-945.
3. American Psychological Association. (2010). Publication manual of the American Psychological Association. Washington, DC: Author.
4. Barlow, D. H., Nock, M. K., & Hersen, M. (2008). Single case experimental designs: Strategies for studying behavior change. Boston: Allyn & Bacon.
5. Baumeister, A. A., Todd, M. E., & Sevin, J. A. (1993). Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation. Clinical Neuropharmacology, 16, 271-294. (Pubitemid 23219893)
6. Birnbrauer, J. S., Peterson, C. R., & Solnick, J. V. (1974). Design and interpretation of studies of single subjects. American Journal of Mental Deficiency, 79, 191-203.
7. Branch, M. N. (1984). Rate dependency, behavioral mechanisms, and behavioral pharmacology. Journal of the Experimental Analysis of Behavior, 42, 511-522.
8. Chassan, J. B. (1976). Research design in clinical psychology and psychiatry. New York: Irvington.
9. Cole, J. O. (1962). Evaluation of drug treatments in psychiatry. Psychopharmacology Service Center Bulletin, 2(3), 28-38.
10. Deb, S., Thomas, M., & Bright, C. (2001). Mental disorder in adults with intellectual disability. I: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research: Special Issue. Mental Health and Intellectual Disability: IX, 45, 495-505. (Pubitemid 33107571)
11. Evans, C. H., & Ildstad, S. T. (Eds.). (2001). Small clinical trials issue and challenges. Washington, DC: National Academies Press.
12. Fabiano, G. A., Pelham, W. E., Jr., Gnagy, E. M., Burrows-MacLean, L., Coles, E. K., Chacko, A., et al. (2007). The single and combined effects of multiple intensities of behavior modification and methylphenidate for children with attention deficit hyperactivity disorder in a classroom setting. School Psychology Review, 36, 195-216.
13. Getz, K., & Zisson, S. (2003). Clinical grant market decelerates. CenterWatch, 10, 4-5.
14. Hanley, G., Piazza, C., Fisher, W., & Maglieri, K. (2005). On the effectiveness of and preference for punishment and extinction components of function-based interventions. Journal of Applied Behavior Analysis, 38, 51-65. (Pubitemid 41529676)
15. Higgins, J., & Green, S. (2006). Cochrane handbook for systematic reviews of interventions 4.2.6. The Cochrane Library (Vol. 4). Chichester, UK: Wiley.
16. Hollon, S. D., & Beck, A. T. (1978). Psychotherapy and drug therapy: Comparison and combinations. In A. Bergin & S. L. Garfield (Eds.), Handbook of psychotherapy and behavior change: An empirical analysis (2nd ed., pp. 437-490). New York: Wiley.
17. Horner, R. H., Carr, E. G., Halle, J., McGee, G., Odom, S., & Wolery, M. (2005). The use of single-subject research to identify evidencebased practice in special education. Exceptional Children, 71, 165-179. (Pubitemid 40273033)
18. Individuals With Disabilities Education Act Amendments of 1997, 20 U. S. C., § 1400 et seq.
19. Iwata, B., Dorsey, M., Slifer, K., Bauman, K., & Richman, G. (1982). Toward a functional analysis of self-injury. Analysis and Intervention in Developmental Disabilities, 2, 3-20.
20. Kahng, S., Iwata, B. A., & Lewin, A. B. (2002). Behavioral treatment of self-injury, 1964 to 2000. American Journal on Mental Retardation, 107, 212-221.
21. Klerman, G. L. (1975). Combining drugs and psychotherapy in the treatment of depression. In M. Greenblatt (Ed.), Drugs in combination with other therapies (pp. 67-81). New York: Grune & Stratton.
22. Lipman, R. S. (1970). The use of psychopharmacological agents in residential facilities for the retarded. In F. J. Menolascino (Ed.), Psychiatric approaches to mental retardation. New York: Basic Books.
23. March, J., Kratochvil, C., Clarke, G., Beardslee, W., Derivan, A., Emslie, G., et al. (2004). AACAP 2002 research forum: Placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 1046-1056. (Pubitemid 38971728)
24. Matson, J. L., Bamburg, J. W., Mayville, E. A., Pinkston, J., Bielecki, J., Kuhn, D., et al. (2000). Psychopharmacology and mental retardation: A 10 year review (1990-1999). Research in Developmental Disabilities, 21, 263-296. (Pubitemid 30665672)
25. Mazumdar, S., Liu, K. S., Houck, P. R., & Reynolds, C. F. (1999). Intent-to-treat analysis for longitudinal clinical trials: Coping with the challenge of missing values. Journal of Psychiatric Research, 33, 87-95. (Pubitemid 29134736)
26. McAdam, D. B., Zarcone, J. R., Hellings, J., Napolitano, D. A., & Schroeder, S. R. (2002). Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. American Journal on Mental Retardation, 107, 261-269. (Pubitemid 34753647)
27. McCannell, K. L., & Duff, H. J. (1995). Drug development, the evaluation of new drugs, and principles of therapeutics. In P. L. Munson, R. A. Mueller & G. R. Breese (Eds.), Textbook of pharmacology (pp. 75-84). New York: Chapman and Hall.
28. Napolitano, D. A., Jack, S. L., Sheldon, J. B., Williams, D. C., McAdam, D. B., & Schroeder, S. R. (1999). Drug-behavior interactions in persons with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 322-334. (Pubitemid 30033621)
29. Nathan, P. E., & Gorman, J. M. (2003). A guide to treatments that work (Vol. 2). New York: Oxford University Press.
30. National Institutes of Health. (2010). Estimates of funding for various research, condition, and disease categories (RCDC). Retrieved July 2010, from http://report.nih.gov/rcdc/categories/popup
31. Normile, D. (2008). Clinical trials guildelines at odds with U. S. policy. Science, 322, 516.
32. O'Leary, K. D., & Borkovec, T. D. (1978). Conceptual, methodological, and ethical problems of placebo groups in psychotherapy research. American Psychologist, 33, 821-830.
33. Pelham, W. E., Jr., & Fabiano, G. A. (2008). Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. Journal of Clinical Child and Adolescent Psychology. Special Issue: Evidence Based Psychosocial Treatments for Children and Adolescents: A Ten Year Update, 37, 184-214.
34. Pelham, W. E., Jr., Fabiano, G. A., & Massetti, G. M. (2005). Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. Journal of Clinical Child and Adolescent Psychology, 34, 449-476. (Pubitemid 41355524)
35. Poling, A., & LeSage, M. (1995). Evaluating psychotropic drugs in people with mental retardation: where are the social validity data? American Journal on Mental Retardation, 100, 193-200.
36. Pyles, D. A. M., Muniz, K., Cade, A., & Silva, R. (1997). A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities, 18, 185-214. (Pubitemid 27282249)
37. Rickels, K., Lipman, R. S., Fisher, S., Park, L. C., & Uhlenhuth, E. H. (1970). Is a double-blind clincial trial really double-blind? A report of doctor's medication guesses. Psychopharmacologia, 16, 329-336.
38. Rinck, C. (1998). Epidemiology and psychoactive medication. In S. Reiss & M. Aman (Eds.), Psychotropic medication and developmental disabilities: The international consensus handbook. Columbus: Ohio State University.
39. Rojahn, J., & Esbensen, A. (2002). Epidemiology of self-injurious behavior in mental retardation. In S. R. Schroeder, M. L. Oster-Granite, & T. Thompson (Eds.), Self-injurious behavior: Gene-brain-behavior relationships (pp. 41-77). Washington, DC: American Psychological Association.
40. Rojahn, J., Schroeder, S. R., & Hoch, T. A. (2008). Self-injurious behavior in intellectual disabilities. Amsterdam: Elsevier.
41. Rush, A. J., & Frances, A. (2000). Expert consensus guidelines: Treatment of psychiatric and behavioral problems in mental retardation. American Journal on Mental Retardation, 104, 159-228.
42. Sandler, A. (2005). Placebo effects in developmental disabilities: Implications for research and practice. Mental Retardation and Developmental Disabilities Research Reviews, 11, 164-170. (Pubitemid 40981698)
43. Scahill, L., Aman, M. G., McDougle, C. J., Arnold, L. E., McCracken, J. T., Handen, B., et al. (2009). Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 39, 720-729.
44. Schaal, D. W., & Hackenberg, T. (1994). Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation, 99, 123-140. (Pubitemid 24300135)
45. Schroeder, S. R. (1999). Psychopharamacology in mental retardation and developmental disabiilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 251-252. (Pubitemid 30033612)
46. Schroeder, S. R., Lewis, M. H., & Lipton, M. A. (1983). Interactions of pharmacotherapy and behavior therapy among children with learning and behavioral disorders. Advances in Learning & Behavioral Disabilities, 2, 179-225.
47. Singh, N. N., & Beale, I. L. (1986). Behavioural assessment of pharmacotherapy. Behaviour Change, 3, 34-40. (Pubitemid 16112467)
48. Sovner, R., & Hurley, A. (1981). The management of chronic behavior disorders in mentally retarded adults with lithium carbonate. Journal of Nervous and Mental Diseases, 169, 191-195. (Pubitemid 11138058)
49. Sprague, R., & Baxley, G. G. (1978). Drugs used for the management of behavior in mental retardation. In J. Wortis (Ed.), Mental retardation (Vol. 8, pp. 92-107). New York: Brunner/Mazel.
50. Sprague, R., & Sleator, E. (1977). Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science, 23, 1274-1276. (Pubitemid 8308550)
51. Sprague, R., & Werry, J. S. (1971). Methology of psychopharmacological studies with the retarded. In N. R. Ellis (Ed.), Internanational review of research in mental retardation (Vol. 5, pp. 148-220). New York: Academic Press.
52. Thompson, T., Hackenberg, T., & Schaal, D. W. (1991). Pharmacological treatments for behavior problems in developmental disabilities. In D. B. Gray & T. Thompson (Eds.), Treatment of desctructive behavior in persons with developmental disabilities (NIH Publication No. 91-2410, pp. 343-440). Bethesda, MD: U. S. Department of Health and Human Services.
53. Tierney, E., Aman, M., Stout, D., Pappas, K., Arnold, L., Vitiello, B., et al. (2007). Parent satisfaction in a multi-site acute trial of risperidone in children with autism: A social validity study. Psychopharmacology, 191, 149-157. (Pubitemid 46294947)
54. Towns, A. J., Singh, N. N., & Beale, I. L. (1984). Reliability of observations in a double-and single-blind drug study: An experimental analysis. Advances in Learning & Behavioral Disabilities, 3, 215-240.
55. Treweek, S., & Zwarenstein, M. (2009). Making trials matter: Pragmatic and explanatory trials and the problem of applicability. Trials, 10, 37.
56. Tunis, S. R., Stryer, D. B., & Clancy, C. M. (2003). Practical clinical trials. Increasing the value of clinical research for decision making in clincial and health policy. Journal of the American Medical Association, 290, 1624-1632. (Pubitemid 37430387)
57. Uhlenhuth, E. H., Lipman, R. S., & Covi, L. (1969). Combined pharmacotherapy and psychotherapy. Journal of Nervous and Mental Disease, 148, 52-64.
58. Unwin, G. L., & Deb, S. (2008). A multi-centre audit of the use of medication for the management of behavioural problems in adults with intellectual disabilities. British Journal of Learning Disabilities, 36, 140-143.
59. U. S. Food and Drug Administration. (2010). Drug study designs. Retrieved July 22, 2010, from http://www.fda.gov/ScienceResearch/SpecialTopics/ RunningClinicalTrials/GuidancesInformation SheetsandNotices/ucm117847.htm
60. Valdovinos, M., Nelson, S. M., Kuhle, J. L., & Dierks, A. M. (2009). Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: A clinical demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2, 279-293.
61. Walker, H. M. (2008, September). Critical issues in the use of randomized clinical trials and control groups with applied settings: Rationale, challenges, and benefits. Paper presented at the Association for Behavior Analysis International Education Conference, Reston, VA.
62. Walkup, J. T., Labellarte, M. J., & Riddle, M. A. (1998). Commentary: Unmasked and uncontrolled medication trials in child and adolescent psychiatry. Journal of the American Academy of Child & Adolescent Psychiatry, 37, 360-363. (Pubitemid 28162888)
63. Werry, J. S. (1978). Pediatric psychopharmacology. New York: Brunner/Mazel.
64. Williams, D. C., & Saunders, K. J. (1997). Methodological issues in the study of drug effects on cognitive skills in mental retardation. In N. W. Bray (Ed.), International review of research in mental retardation (Vol. 21, pp. 147-185). New York: Academic Press.
65. Wolf, M. M. (1978). Social validity: The case for subjective measurement or how applied behavior analysis is finding its heart. Journal of Applied Behavior Analysis, 11, 203-214.
66. Wright, C. C., & Sim, J. (2003). Intention-to-treat approach to data from randomized controlled trials: A sensitivity analysis. Jounal of Clinical Epidemiology, 56, 833-842. (Pubitemid 37162657)
67. Zarcone, J., Hellings, J., Crandall, K., Reese, R. M., Marquis, J., Fleming, K., et al. (2001). Effects of risperidone on abberant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal on Mental Retardation, 106, 525-538. (Pubitemid 34003384)
68. Zarcone, J., Napolitano, D., & Valdovinos, M. (2008). Measurement of problem behaviour during medication evaluations. Journal of Intellectual Disability Research, 52, 1015-1028.